BioSig lands Commercial Sales to Leading Hospital System
April 06 2021 - 9:45AM
- World class healthcare institution adopts PURE
EP™ across multiple States
- Medical centers resuming elective procedures helps
drive sales acceleration
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that a top rated leading hospital system
purchased PURE EP™ systems for multiple campuses in their national
network.
“We are pleased to expand our commercial installations across
this most important healthcare system in multiple states.”
commented Kenneth L. Londoner, Chairman, and CEO of BioSig
Technologies, Inc. “We expect to see further commercial sales
in coming weeks and months”
More than 680 patient cases have been conducted with the PURE
EP™ System to date across eight clinical sites. The PURE EP™
System is being used in all types of arrhythmia cases, including
atrial fibrillation, ventricular tachycardia, and atrial flutter.
The Company continues to accumulate significant amounts of
data to be utilized in the development of its AI platform.
The Company previously announced that it completed its first
commercial sale of PURE EP™ Systems to St. David’s HealthCare of
Austin, Texas, an HCA Healthcare-owned hospital. “We are excited to
see leading electrophysiologists and institutions commercially
adopt the PURE EP™ system which we believe demonstrates acceptance
of the unique benefits of our system platform, software, and data,”
added Londoner. About BioSig Technologies BioSig
Technologies is a medical technology company commercializing a
proprietary biomedical signal processing platform designed
to improve signal fidelity and uncover the full range of ECG
and intra-cardiac signals (www.biosig.com).
The Company’s first product, PURE EP™ System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Follow BioSig Technologies, Inc. on Twitter
at @Biosig_tech
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024